Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection

Riedel, David J.; Gonzalez‐Cuyar, Luis F.; Zhao, X. Frank; Redfield, Robert; Gilliam, Bruce L.

doi:10.1016/s1473-3099(08)70067-7

Cited by 66 publications

(103 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Radiographically, PBL is characterized by an expansile, highly destructive, lytic lesion in the affected areas with overlying swelling of the soft tissues [10]. Moreover; MDCT shows perineural extension, lymphadenopathy as well as infiltration to the adjacent facial spaces as shown in the present case.…”

Section: Discussionsupporting

confidence: 64%

“…PBL has been well known for its frequency in the oral cavity of HIV-positive individuals [10]. However, HIV-positive patients may experience PBL as an extraoral involvement, such as skull, paranasal sinuses, bone, skin, subcutaneous tissues, gastrointestinal tract (GIT), central nervous system, lungs, mediastinum, and various lymph nodes [5].…”

Section: Discussionmentioning

confidence: 99%

“…However, HIV-positive patients may experience PBL as an extraoral involvement, such as skull, paranasal sinuses, bone, skin, subcutaneous tissues, gastrointestinal tract (GIT), central nervous system, lungs, mediastinum, and various lymph nodes [5]. Lymph nodes, skin and GIT are the most affected extraoral sites [5,10]. Similarly, oral cavity and GIT are the most involved sites in HIV-negative PBL patients [5].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Multidetector Computed Tomography Features of Plasmablastic Lymphoma of the Oral Cavity in an HIV-Positive Patient

MJ¹,

Barghan²,

Mk³

2018

IJDOS

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 64%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Multidetector Computed Tomography Features of Plasmablastic Lymphoma of the Oral Cavity in an HIV-Positive Patient

MJ¹,

Barghan²,

Mk³

2018

IJDOS

View full text Add to dashboard Cite

“…PBL is a rapidly progressive lymphoma, and delay in treatment can adversely impact patient survival [7]. Although prompt and accurate recognition of PBL is imperative, the diagnosis of PBL is not easy due to a variety of contributing factors.…”

Section: Discussionmentioning

confidence: 99%

“…PBL is regarded as very aggressive neoplasm, and it usually presents at an advanced stage. Although the rarity of PBL has not permitted the development of a standardized treatment [4,5], a combination of highly active anti-retroviral therapy and chemotherapy may lead to improved patient outcomes [5,7].…”

Section: Introductionmentioning

confidence: 99%

Plasmablastic Lymphoma Involving the Parotid Gland

Bishop

Westra

2010

Head and Neck Pathol

View full text Add to dashboard Cite

Plasmablastic lymphoma is a rare form of nonHodgkin lymphoma. It is strongly associated with HIV infection, although it has been recognized in immunocompetent patients. Plasmablastic lymphoma has a predilection for the oral cavity. Its occurrence in the parotid gland has not been previously described. We report a case of an HIV positive man who developed a rapidly enlarging parotid mass. A core biopsy of the parotid mass was evaluated by routine microscopy, immunohistochemistry, and in situ hybridization. The tumor was comprised of sheets of large cells with abundant cytoplasm, eccentric nuclei and prominent nucleoli. The cells exhibited a plasmacytic immunophenotype including expression for CD38 and CD138. An in situ hybridization assay for Epstein-Barr virus was positive. These findings were diagnostic of plasmablastic lymphoma. Plasmablastic lymphoma is notoriously difficult to diagnose, particularly when it arises in unexpected sites outside of the oral cavity. As an aggressive lymphoma, plasmablastic lymphoma must be considered in the differential diagnosis of a high-grade malignant neoplasm not just in the oral cavity but at non-oral sites including the parotid gland, particularly in an HIV-positive individual.

show abstract

Survival analysis in treated plasmablastic lymphoma patients: a population‐based study

2020

View full text Add to dashboard Cite

Herein we analyzed survival outcomes in chemotherapy-treated patients with plasmablastic lymphoma (PBL) diagnosed between 2010 to 2016 (n = 248). Data was acquired from the Surveillance, Epidemiology, and End Results (SEER) 18 registries database (April 2019 release based on November 2018 submission). The majority of patients were male (81.9%) and younger than 60 years (71.0%). Oral and gastrointestinal (GI) sites were the most frequent primary extranodal locations (23% and 19.4%, respectively). Oral primary location was inversely associated with presence of B symptoms and advanced Ann-Arbor stage. The 3-year and 5-year overall survival (OS) rates of treated PBL patients were 54% (95% CI: 46.5%-60.8%) and 52.8% (95% CI: 45.2%-59.8%). Three-year conditional survival for 2-year and 3-year survivors were 90.3% and 97.8%, overlapping the survival of a general population matched by age, sex and calendar year. In a multivariable analysis, oral primary location was associated with not only better OS (HR 0.43; 95% CI: 0.21-0.88, P = .021) but also better lymphoma-specific survival (LSS) (SHR 0.36; 95% CI: 0.15-0.86, P = .022); age ≥60 years was associated with shorter LSS (SHR 1.73; 95% CI: 1.02-2.96, P = .043). Seven registries granted access to HIV status (n = 93) where HIV infection was detected in 52.7% of cases. The HIV status did not affect survival outcomes in unadjusted and adjusted analyses. We identified clinical characteristics associated with survival and showed that treated PBL patients may achieve long-term survival. 1 | INTRODUCTION Plasmablastic lymphoma (PBL) is a rare aggressive non-Hodgkin lymphoma with unknown incidence. Plasmablastic lymphoma was first described as a distinct clinicopathological entity in 1997 by Delecluse et al. and was shown to be associated with HIV infection (15 of 16 cases), Epstein-Barr virus (EBV) infection (9 of 16 cases) and a predilection for oral cavity, particularly jaw mucosa. 1 Subsequently, PBL was described in non-HIV patients with primary involvement outside of the oral cavity and was incorporated as a distinct clinical lymphoma type into the latest World Health Organization lymphoma classification. 2 It is considered to be a subtype of large B-cell lymphoma with plasmablastic morphology and expression of plasma cell markers (CD79a, CD38, CD138 and MUM-1), but lacking expression of B-cell markers (CD20, PAX-5). 3 The differential diagnosis includes immunoblastic diffuse large B-cell lymphoma, ALK positive diffuse large B-cell lymphoma, HHV-8 positive large B-cell lymphoma, primary effusion lymphoma, plasmablastic or anaplastic multiple myeloma and undifferentiated carcinoma. 3-5 Nodal involvement and association with HIV and EBV are typical for PBL but not seen in plasma cell neoplasms. 5-7 Plasmablastic lymphoma is an aggressive lymphoma with overall survival (OS) ranging from 7 to 62 months, according to small Jorge A. Florindez and Juan Pablo Alderuccio contributed equally to this study.

show abstract

Plasmablastic lymphoma of the oral cavity: a rapidly progressive lymphoma associated with HIV infection

Cited by 66 publications

References 55 publications

Multidetector Computed Tomography Features of Plasmablastic Lymphoma of the Oral Cavity in an HIV-Positive Patient

Multidetector Computed Tomography Features of Plasmablastic Lymphoma of the Oral Cavity in an HIV-Positive Patient

Plasmablastic Lymphoma Involving the Parotid Gland

Survival analysis in treated plasmablastic lymphoma patients: a population‐based study

Contact Info

Product

Resources

About